For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $8.4 in the prior trading day, Novavax, Inc (NASDAQ: NVAX) closed at $7.91, down -5.83%. In other words, the price has decreased by -$5.83 from its previous closing price. On the day, 4.3 million shares were traded. NVAX stock price reached its highest trading level at $8.4 during the session, while it also had its lowest trading level at $7.8808.
Ratios:
Our goal is to gain a better understanding of NVAX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.34 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 6.07 whereas as Long-Term Debt/Eq ratio is at 5.93.
BofA Securities Downgraded its Neutral to Underperform on August 20, 2025, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1284755200 and an Enterprise Value of 900941184. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.50, and their Forward P/E ratio for the next fiscal year is 117.57. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.19 while its Price-to-Book (P/B) ratio in mrq is 34.09. Its current Enterprise Value per Revenue stands at 0.835 whereas that against EBITDA is 2.211.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.69, which has changed by -0.11016947 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $11.55, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is -5.71%, while the 200-Day Moving Average is calculated to be 3.93%.
Shares Statistics:
The stock has traded on average 5.99M shares per day over the past 3-months and 3390650 shares per day over the last 10 days, according to various share statistics. A total of 162.16M shares are outstanding, with a floating share count of 148.05M. Insiders hold about 8.85% of the company’s shares, while institutions hold 58.76% stake in the company. Shares short for NVAX as of 1760486400 were 45828036 with a Short Ratio of 7.65, compared to 1757894400 on 44723391. Therefore, it implies a Short% of Shares Outstanding of 45828036 and a Short% of Float of 28.32.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.27, with high estimates of $0.0 and low estimates of -$0.92.
Analysts are recommending an EPS of between $2.77 and $1.27 for the fiscal current year, implying an average EPS of $2.16. EPS for the following year is $0.04, with 8.0 analysts recommending between $2.72 and -$1.3.
Revenue Estimates
6 analysts predict $44.87M in revenue for. The current quarter. It ranges from a high estimate of $63M to a low estimate of $31M. As of. The current estimate, Novavax, Inc’s year-ago sales were $84.51MFor the next quarter, 6 analysts are estimating revenue of $105.16M. There is a high estimate of $155.7M for the next quarter, whereas the lowest estimate is $63.5M.
A total of 8 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.1B, while the lowest revenue estimate was $1.02B, resulting in an average revenue estimate of $1.05B. In the same quarter a year ago, actual revenue was $682.16MBased on 9 analysts’ estimates, the company’s revenue will be $428.08M in the next fiscal year. The high estimate is $923.2M and the low estimate is $291.69M.
